CN106680411A - 一种用于检测系统性红斑狼疮（sle)的试剂盒及其检测方法 - Google Patents

一种用于检测系统性红斑狼疮（sle)的试剂盒及其检测方法 Download PDF

Info

Publication number
CN106680411A
CN106680411A CN201710167338.XA CN201710167338A CN106680411A CN 106680411 A CN106680411 A CN 106680411A CN 201710167338 A CN201710167338 A CN 201710167338A CN 106680411 A CN106680411 A CN 106680411A
Authority
CN
China
Prior art keywords
sle
c4bpa
lupus erythematosus
aptamer
systemic lupus
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
CN201710167338.XA
Other languages
English (en)
Other versions
CN106680411B (zh
Inventor
申冬昌
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Han's joint (Tianjin) Stem Cell Research Institute Co., Ltd.
Original Assignee
申冬昌
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 申冬昌 filed Critical 申冬昌
Priority to CN201710167338.XA priority Critical patent/CN106680411B/zh
Publication of CN106680411A publication Critical patent/CN106680411A/zh
Application granted granted Critical
Publication of CN106680411B publication Critical patent/CN106680411B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N30/00—Investigating or analysing materials by separation into components using adsorption, absorption or similar phenomena or using ion-exchange, e.g. chromatography or field flow fractionation
    • G01N30/02—Column chromatography
    • G01N30/88—Integrated analysis systems specially adapted therefor, not covered by a single one of the groups G01N30/04 - G01N30/86
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/115—Aptamers, i.e. nucleic acids binding a target molecule specifically and with high affinity without hybridising therewith ; Nucleic acids binding to non-nucleic acids, e.g. aptamers
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6803—General methods of protein analysis not limited to specific proteins or families of proteins
    • G01N33/6827—Total protein determination, e.g. albumin in urine
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6803—General methods of protein analysis not limited to specific proteins or families of proteins
    • G01N33/6848—Methods of protein analysis involving mass spectrometry
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/16—Aptamers
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N30/00—Investigating or analysing materials by separation into components using adsorption, absorption or similar phenomena or using ion-exchange, e.g. chromatography or field flow fractionation
    • G01N30/02—Column chromatography
    • G01N30/88—Integrated analysis systems specially adapted therefor, not covered by a single one of the groups G01N30/04 - G01N30/86
    • G01N2030/8809—Integrated analysis systems specially adapted therefor, not covered by a single one of the groups G01N30/04 - G01N30/86 analysis specially adapted for the sample
    • G01N2030/8813—Integrated analysis systems specially adapted therefor, not covered by a single one of the groups G01N30/04 - G01N30/86 analysis specially adapted for the sample biological materials
    • G01N2030/8822—Integrated analysis systems specially adapted therefor, not covered by a single one of the groups G01N30/04 - G01N30/86 analysis specially adapted for the sample biological materials involving blood
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N30/00—Investigating or analysing materials by separation into components using adsorption, absorption or similar phenomena or using ion-exchange, e.g. chromatography or field flow fractionation
    • G01N30/02—Column chromatography
    • G01N30/88—Integrated analysis systems specially adapted therefor, not covered by a single one of the groups G01N30/04 - G01N30/86
    • G01N2030/8809—Integrated analysis systems specially adapted therefor, not covered by a single one of the groups G01N30/04 - G01N30/86 analysis specially adapted for the sample
    • G01N2030/8813—Integrated analysis systems specially adapted therefor, not covered by a single one of the groups G01N30/04 - G01N30/86 analysis specially adapted for the sample biological materials
    • G01N2030/8831—Integrated analysis systems specially adapted therefor, not covered by a single one of the groups G01N30/04 - G01N30/86 analysis specially adapted for the sample biological materials involving peptides or proteins
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/10—Musculoskeletal or connective tissue disorders
    • G01N2800/101—Diffuse connective tissue disease, e.g. Sjögren, Wegener's granulomatosis
    • G01N2800/104—Lupus erythematosus [SLE]

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Physics & Mathematics (AREA)
  • Biomedical Technology (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Urology & Nephrology (AREA)
  • Immunology (AREA)
  • Genetics & Genomics (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • Hematology (AREA)
  • Biophysics (AREA)
  • Pathology (AREA)
  • Bioinformatics & Computational Biology (AREA)
  • Microbiology (AREA)
  • General Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicinal Chemistry (AREA)
  • Food Science & Technology (AREA)
  • Cell Biology (AREA)
  • General Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Organic Chemistry (AREA)
  • Spectroscopy & Molecular Physics (AREA)
  • Plant Pathology (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)

Abstract

本发明公开了一种用于检测系统性红斑狼疮（SLE)的试剂盒及其检测方法，该试剂盒含有能特异性检测系统性红斑狼疮（SLE)的适配子，该适配子能特异性结合C4BPA。本发明的试剂盒能够用于定量检测C4BPA蛋白的表达量，从而能够用于精确检测系统性红斑狼疮疾病。

Description

一种用于检测系统性红斑狼疮(SLE)的试剂盒及其检测方法
技术领域
本发明涉及一种用于检测系统性红斑狼疮(SLE)的试剂盒及其检测方法。
背景技术
系统性红斑狼疮(SLE)是自体免疫病因学(auto immune etiology)的炎症性紊乱，主要发生在年轻女性中。SLE能影响许多的身体器官系统，包括肾、皮肤、关节、神经系统、浆膜、血细胞和脉管。虽然不清楚SLE的具体诱因，但许多因素与疾病的发展有关，包括基因、种族、激素和环境因素。
多种类型抗核抗体的存在是患SLE的重要血清学特点，所以目前SLE的快速诊断主要是依据血清自身抗体检查，再结合以临床表现观察。其中抗核抗体(ANA)对SLE的敏感性为95％，特异性大约为65％，是目前最佳的SLE病情筛选指标，如多次呈阴性，则患SLE的可能性不大；抗双链DNA抗体(dsDNA)对SLE的特异性高达95％，敏感性约为70％，对确诊SLE和判断狼疮活动具有较大的参考价值；抗Sm抗体对SLE的特异性高达99％，但敏感性仅为25％，在SLE不活动时也可呈阳性，故多作为回顾性诊断的重要根据；此外抗单链DNA抗体(ss-DNA)也可作为SLE诊断指标之一。目前临床血检中对以上所述四种指标的检测，主要是采用放射免疫测定法(RIA)，虽然其具有较好的灵敏度、特异性和稳定性，但检测过程较为烦琐，操作不便，而且每次也只能分析一种指标，历时较长，所提供的诊断信息量有限而不全面，诸多的不足为临床诊断和治疗带来了不便。
CN 104655852 A中公开了一种特异性检测血清抗体中高甘露糖型N糖链水平的试剂在制备用于系统性红斑狼疮的诊断和/或预后评估的诊断工具中的应用。所述血清抗体中高甘露糖型N糖链水平的增高与系统性红斑狼疮的发生密切相关，可用于系统性红斑狼疮的早期诊断和/或预后评估，进而用于指导系统性红斑狼疮的治疗。但是该方法在小鼠层面上进行的实验，在人体中是否能够具有相应的鉴定效果无法预期。
CN 105229470 A公开了用于诊断、预后和治疗系统性红斑狼疮(SLE)的方法和试剂，其涉及根据红细胞C4d(EC4d)标志物、B细胞C4d(BC4d)标志物、抗核抗体(ANA)。该方法中涉及了众多的标志物检测种类较多，而且检测不便。
目前，临床治疗复杂的自身免疫性疾病(如SLE)的最艰巨的挑战之一是患者的疾病的准确和早期鉴别。此外，没有鉴别出使临床医师或其他人能够准确地确定SLE的病理生理表现、临床活动、对治疗的响应或预后的可靠性诊断标记。
发明内容
一种非诊断目的的系统性红斑狼疮阶段性蛋白表达差异图谱模型的构建方法，包括如下步骤:分别采集系统性红斑狼疮患者组、健康对照组的外周血单个核细胞标本；分别对各所述外周血单个核细胞标本进行细胞总蛋白抽提和蛋白浓度测定；将所述细胞总蛋白经蛋白酶消化后，用相对和绝对定量的等量异位标签标记，得到相对和绝对定量的等量异位标签多重标记的多肽；将所述多肽经强阳离子交换和反相液相色谱分离，再进行串联质谱鉴定和相对定量分析，得到所述系统性红斑狼疮阶段性蛋白表达差异图谱模型，通过表型鉴定，最终分析得到了SERPINA6和C4BPA这两个蛋白，以该蛋白作为生物标志物对其表达量进行检测可以用于指导SLE患者中的早期诊断。
本发明另外提供了SERPINA6和C4BPA这两个蛋白用于制备SLE患者诊断的标志物。
另外，本发明对C4BPA在系统性红斑狼疮病人血液中的表达进行了定量检测。
另外一方面，本发明提供了一种特异性的识别C4BPA的适配子，其序列如SEQ IDNO：1-13所示。
另外一方面，本发明提供一种试剂盒，用于特异性的诊断系统性红斑狼疮，其包含如SEQ ID NO：1-13所示的序列。
另外一方面，所述的适配子偶联有磁珠以及筛选标记。
有益效果:本发明通过差异蛋白筛选，实验结果表明C4BPA在系统性红斑狼疮出现明显上调表达，可作为系统性红斑狼疮疾病临床诊断标志物。并且本发明通过特异性的筛选获得了C4BPA蛋白特异性结合的适配子，能够用于定量检测C4BPA蛋白的表达量，从而能够用于精确检测系统性红斑狼疮疾病。
附图说明
图1是患者血液和健康对照组血液中C4BPA的浓度的统计分析图。
图2是ROC曲线显示蛋白诊断系统性红斑狼疮的特异性和灵敏度。
具体实施方式
下面结合附图对本发明提供的具体实施方式作详细说明。
实施例1
分别采集系统性红斑狼疮患者20例、健康对照组20例的外周血单个核细胞标本；分别对各所述外周血单个核细胞标本进行细胞总蛋白抽提和蛋白浓度测定；将所述细胞总蛋白经蛋白酶消化后，用相对和绝对定量的等量异位标签标记，得到相对和绝对定量的等量异位标签多重标记的多肽；将所述多肽经强阳离子交换和反相液相色谱分离，再进行串联质谱鉴定和相对定量分析，得到所述系统性红斑狼疮阶段性蛋白表达差异图谱模型，通过表型鉴定，最终分析得到了SERPINA6和C4BPA这两个蛋白，差异表达显著，可以作为生物标志物对其表达量进行检测可以用于指导SLE患者中的早期诊断。
另外测量患者血清中C4BPA浓度明显高于对照组血清(P＜0.05)，参见图1。
另外，根据图2 ROC曲线设定了C4BPA的cut-off值为100.9ng/ml，AUC达到了0.9823，其敏感性和特异性均大于94％，阳性率为96.5％。统计分析结果显示，血液中C4BPA浓度与系统性红斑狼疮密切相关，综合上述实验研究，可以得出结论，C4BPA在系统性红斑狼疮患者中高分泌，可以作为C4BPA和正常人群区分的一个特别好的标志物。
实施例2适配子的获得
采用SELEX技术，筛选得到了特异性结合C4BPA蛋白的适配子，其序列如下文库为TACGTAGAATGACTCGTGAG(N)35CAGTACGATGGATGCAGTGA
C4BPA-1：
TACGTAGAATGACTCGTGAGCTCCACCAACCTCTTCTACTACATATATTCAAAACCAGTACGATGGATGCAGTGA
C4BPA-2：
TACGTAGAATGACTCGTGAGTCTCCTCCATTCATCCTCAAAATACTATTATCACTCAGTACGATGGATGCAGTGA
C4BPA-3：
TACGTAGAATGACTCGTGAGAATTTAATCTAAAACCCATATTTTCCACCACATTACAGTACGATGGATGCAGTGA
C4BPA-4：
TACGTAGAATGACTCGTGAGCCCATCTATCCTCCATTTCATTTACTAACCCCAAACAGTACGATGGATGCAGTGA
C4BPA-5：
TACGTAGAATGACTCGTGAGCACCTAAACATACTATACTTTAATTTAACTCCACTCAGTACGATGGATGCAGTGA
C4BPA-6：
TACGTAGAATGACTCGTGAGCTTTATCAAACAACACTTCATTTTCCCAATATTATCAGTACGATGGATGCAGTGA
C4BPA-7：
TACGTAGAATGACTCGTGAGATCATCACTCCACCCTACCCTTCCTCCCCAAACAACAGTACGATGGATGCAGTGA
C4BPA-8：
TACGTAGAATGACTCGTGAGTTCCTTTTTCTAACCATAACCTTCCCATCAATCTCCAGTACGATGGATGCAGTGA
C4BPA-9：
TACGTAGAATGACTCGTGAGTTCTAACTTACAATCTCTTTTTAATCTCATACCATCAGTACGATGGATGCAGTGA
C4BPA-10：
TACGTAGAATGACTCGTGAGAAAACTATTATATTCCTTTATACTATAATTTTACCCAGTACGATGGATGCAGTGA
C4BPA-11：
TACGTAGAATGACTCGTGAGATTATATCCACTAATCAAACCCATAAACTATTATCCAGTACGATGGATGCAGTGA
C4BPA-12：
TACGTAGAATGACTCGTGAGATCACTACATCATCACACTTTAACCACATCCCCTCCAGTACGATGGATGCAGTGA
C4BPA-13：
TACGTAGAATGACTCGTGAGCTCATTTCTCAATTCCCAACTTCAACCCCACCCCCCAGTACGATGGATGCAGTGA
实施例3蛋白结合适配子的性能测定
基于氧化石墨烯氧化具有吸附单链DNA的特性，构建了寡核苷酸适配子亲和性验证方法。将固定浓度的C4BPA蛋白靶标(1μΜ)分别与与其对应一系列不同浓度(10，25，50，75，100，150，200uΜ)的候选寡核苷酸适配子进行孵育，总体积为300uL，37℃避光孵育2h，并以BB缓冲液代替靶标作为阴性对照组。孵育结合后加入最佳用量比的GO吸附未与靶标结合的适配子，离心操作后采用F-7000荧光光度计测定上清液490nm激发下520nm发射的荧光强度，实验设置三次平行重复，实验采用避光处理。以实验组相对阴性对照组的荧光强度作为纵坐标，以适配子浓度作为横坐标，采用GraphPad Prism 5.0软件进行非线性回归拟合计算适配子的解离常数Kd值。结果如下：
另外，通过与血清中其它人体的蛋白相接触，本发明提供的适配子具有较好的结合特异性和稳定性，同时也没有任何溶血性，具有较好的生物学特性。
实施例4所述适配子疾病的诊断
将13个适配子分别与12个系统性红斑狼疮患者患者进行检测。
在酶标板孔中加入12个血清样品以及对照健康样本包被，并加入通过生物素标记的适配子13个，加入HRP标记的链酶亲和素，37℃孵育1.5小时；PBS洗三次后加入TMB进行显色5分钟；2M硫酸终止反应后酶标仪读数；进行检测，结果所示，与健康志愿者相比，系统性红斑狼疮患者血清中C4BPA蛋白的0D450均明显升高(p＝0.0035)。通过标准曲线，计算得出，血清中C4BPA蛋白浓度均大于100.9ng/ml，而正常人群的C4BPA蛋白浓度均远远小于100.9ng/ml，结果证明13个适配子在系统性红斑狼疮诊断中具有应用前景。
以上仅为本发明的优选实施例而已，并不用于限制本发明，对于本领域的技术人员来说，凡在本发明的精神和原则之内所做的任何修改、等同替换、改进等，均应包含在本发明的保护范围之内。
序列表
〈110〉申冬昌
〈120〉一种用于检测系统性红斑狼疮（SLE)的试剂盒及其检测方法
〈160〉13
〈210〉1
〈211〉75
〈212〉DNA
〈213〉人工序列
〈400〉C4BPA-1
TACGTAGAATGACTCGTGAGCTCCACCAACCTCTTCTACTACATATATTCAAAACCAGTACGATGGATGCAGTGA
〈210〉2
〈211〉75
〈212〉DNA
〈213〉人工序列
〈400〉C4BPA-2
TACGTAGAATGACTCGTGAGTCTCCTCCATTCATCCTCAAAATACTATTATCACTCAGTACGATGGATGCAGTGA
〈210〉3
〈211〉75
〈212〉DNA
〈213〉人工序列
〈400〉C4BPA-3
TACGTAGAATGACTCGTGAGAATTTAATCTAAAACCCATATTTTCCACCACATTACAGTACGATGGATGCAGTGA
〈210〉4
〈211〉75
〈212〉DNA
〈213〉人工序列
〈400〉C4BPA-4
TACGTAGAATGACTCGTGAGCCCATCTATCCTCCATTTCATTTACTAACCCCAAACAGTACGATGGATGCAGTGA
〈210〉5
〈211〉75
〈212〉DNA
〈213〉人工序列
〈400〉C4BPA-5
TACGTAGAATGACTCGTGAGCACCTAAACATACTATACTTTAATTTAACTCCACTCAGTACGATGGATGCAGTGA
〈210〉6
〈211〉75
〈212〉DNA
〈213〉人工序列
〈400〉C4BPA-6
TACGTAGAATGACTCGTGAGCTTTATCAAACAACACTTCATTTTCCCAATATTATCAGTACGATGGATGCAGTGA
〈210〉7
〈211〉75
〈212〉DNA
〈213〉人工序列
〈400〉C4BPA-7
TACGTAGAATGACTCGTGAGATCATCACTCCACCCTACCCTTCCTCCCCAAACAACAGTACGATGGATGCAGTGA
〈210〉8
〈211〉75
〈212〉DNA
〈213〉人工序列
〈400〉C4BPA-8
TACGTAGAATGACTCGTGAGTTCCTTTTTCTAACCATAACCTTCCCATCAATCTCCAGTACGATGGATGCAGTGA
〈210〉9
〈211〉75
〈212〉DNA
〈213〉人工序列
〈400〉C4BPA-9
TACGTAGAATGACTCGTGAGTTCTAACTTACAATCTCTTTTTAATCTCATACCATCAGTACGATGGATGCAGTGA
〈210〉10
〈211〉75
〈212〉DNA
〈213〉人工序列
〈400〉C4BPA-10
TACGTAGAATGACTCGTGAGAAAACTATTATATTCCTTTATACTATAATTTTACCCAGTACGATGGATGCAGTGA
〈210〉11
〈211〉75
〈212〉DNA
〈213〉人工序列
〈400〉C4BPA-11
TACGTAGAATGACTCGTGAGATTATATCCACTAATCAAACCCATAAACTATTATCCAGTACGATGGATGCAGTGA
〈210〉12
〈211〉75
〈212〉DNA
〈213〉人工序列
〈400〉C4BPA-12
TACGTAGAATGACTCGTGAGATCACTACATCATCACACTTTAACCACATCCCCTCCAGTACGATGGATGCAGTGA
〈210〉13
〈211〉75
〈212〉DNA
〈213〉人工序列
〈400〉C4BPA-13
TACGTAGAATGACTCGTGAGCTCATTTCTCAATTCCCAACTTCAACCCCACCCCCCAGTACGATGGATGCAGTGA

Claims (5)

1.一种用于检测系统性红斑狼疮（SLE)的试剂盒，其特征在于：含有能特异性检测系统性红斑狼疮（SLE)的适配子。
2.如权利要求1所述的试剂盒，其特征在于：所述适配子能特异性结合C4BPA。
3. 如权利要求2所述的试剂盒，其特征在于：所述适配子的序列如SEQ ID NO：1-13任一所示。
4. 一种适配子，其特征在于：序列如SEQ ID NO：1-13任一所示。
5.权利要求4所述的适配子在制备用于检测系统性红斑狼疮（SLE)的试剂盒的应用。
CN201710167338.XA 2017-03-20 2017-03-20 一种用于检测系统性红斑狼疮(sle)的试剂盒及其检测方法 Active CN106680411B (zh)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CN201710167338.XA CN106680411B (zh) 2017-03-20 2017-03-20 一种用于检测系统性红斑狼疮(sle)的试剂盒及其检测方法

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CN201710167338.XA CN106680411B (zh) 2017-03-20 2017-03-20 一种用于检测系统性红斑狼疮(sle)的试剂盒及其检测方法

Publications (2)

Publication Number Publication Date
CN106680411A true CN106680411A (zh) 2017-05-17
CN106680411B CN106680411B (zh) 2018-10-09

Family

ID=58829244

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201710167338.XA Active CN106680411B (zh) 2017-03-20 2017-03-20 一种用于检测系统性红斑狼疮(sle)的试剂盒及其检测方法

Country Status (1)

Country Link
CN (1) CN106680411B (zh)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN109470853A (zh) * 2017-09-08 2019-03-15 广州市丹蓝生物科技有限公司 自身免疫疾病诊断用液相蛋白芯片、试剂盒及制作方法
CN115960904A (zh) * 2022-11-16 2023-04-14 广东省中医院（广州中医药大学第二附属医院、广州中医药大学第二临床医学院、广东省中医药科学院） 一种基于特异性核酸适配体的抗dsDNA抗体电化学检测方法

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2014151238A1 (en) * 2013-03-15 2014-09-25 Exagen Diagnostics, Inc. Methods for treating and diagnosing systemic lupus erythematosus
CN104177488A (zh) * 2014-07-13 2014-12-03 马海龙 一种特异性针对Neutrokine-α蛋白的核酸适配体及其应用
US20150133469A1 (en) * 2012-03-13 2015-05-14 Baylor Research Institute Early detection of tuberculosis treatment response
CN104655852A (zh) * 2013-11-21 2015-05-27 苏州中赢医疗科技有限公司 一种系统性红斑狼疮的诊断标志
CN105753943A (zh) * 2016-02-18 2016-07-13 苏州偲聚生物材料有限公司 可用于诊断系统性红斑狼疮的检测器件、检测试剂盒及诊断方法

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20150133469A1 (en) * 2012-03-13 2015-05-14 Baylor Research Institute Early detection of tuberculosis treatment response
WO2014151238A1 (en) * 2013-03-15 2014-09-25 Exagen Diagnostics, Inc. Methods for treating and diagnosing systemic lupus erythematosus
CN105229470A (zh) * 2013-03-15 2016-01-06 艾克斯肯诊断股份有限公司 用于治疗和诊断系统性红斑狼疮的方法
CN104655852A (zh) * 2013-11-21 2015-05-27 苏州中赢医疗科技有限公司 一种系统性红斑狼疮的诊断标志
CN104177488A (zh) * 2014-07-13 2014-12-03 马海龙 一种特异性针对Neutrokine-α蛋白的核酸适配体及其应用
CN105753943A (zh) * 2016-02-18 2016-07-13 苏州偲聚生物材料有限公司 可用于诊断系统性红斑狼疮的检测器件、检测试剂盒及诊断方法

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
A.-K. B. LINDQVIST 等: "The Genetics of Systemic Lupus Erythematosus", 《SCAND. J. IMMUNOL.》 *
张妍 等: "系统性红斑狼疮患者血清蛋白质组学研究", 《标记免疫分析与临床》 *

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN109470853A (zh) * 2017-09-08 2019-03-15 广州市丹蓝生物科技有限公司 自身免疫疾病诊断用液相蛋白芯片、试剂盒及制作方法
CN115960904A (zh) * 2022-11-16 2023-04-14 广东省中医院（广州中医药大学第二附属医院、广州中医药大学第二临床医学院、广东省中医药科学院） 一种基于特异性核酸适配体的抗dsDNA抗体电化学检测方法

Also Published As

Publication number Publication date
CN106680411B (zh) 2018-10-09

Similar Documents

Publication Publication Date Title
JP6452718B2 (ja) 食物アレルギーを検出するためのペプチド、試薬及び方法
KR102289278B1 (ko) 췌장암 진단용 바이오마커 패널 및 그 용도
WO2006113245B1 (en) Methods for measuring glycan levels of proteins
WO2011143597A1 (en) Methods and devices for diagnosing alzheimers disease
Christenson et al. Methodological and analytic considerations for blood biomarkers
JP2022512890A (ja) 試料の品質評価方法
Svedberg et al. Towards encoded particles for highly multiplexed colorimetric point of care autoantibody detection
CN106680411B (zh) 一种用于检测系统性红斑狼疮(sle)的试剂盒及其检测方法
Chao et al. Towards proteome standards: the use of absolute quantitation in high-throughput biomarker discovery
CN110716050A (zh) 抗原组合在制备用于肺癌相关自身抗体检测的试剂盒中的用途以及相应的试剂盒和检测方法
CN105308455B (zh) 用于诊断先兆子痫的方法和组合物
EP2784511A1 (en) Integrin alpha-v-beta6 for diagnosis/prognosis of colorectal carcinoma
CN112684183A (zh) 一种多抗原蛋白组合应用于肺结核的鉴别与诊断
Araujo et al. A novel reactive epitope-based antigen targeted by serum autoantibodies in oligoarticular and polyarticular juvenile idiopathic arthritis and development of an electrochemical biosensor
CN113125757B (zh) 一种用于母猪早期妊娠诊断的蛋白生物标志物及其用于母猪早期妊娠检测的方法
CN106908600B (zh) 一种用于检测系统性红斑狼疮(sle)的试剂盒
US10781488B1 (en) Test kit for detecting concentration of cardiovascular disease-related biomarker and concentration detection method for detecting concentration of cardiovascular disease-related biomarker
US10488393B2 (en) Device and method for self-referenced confidence test
KR101552011B1 (ko) 리소포스파티딜콜린 및 호모시스테인산을 포함하는 난소암 진단용 조성물 및 이를 사용하여 난소암을 진단하는 방법
CN109725156A (zh) 多肽sle2018-v002在诊断系统性红斑狼疮试剂盒中的应用
RU2702900C1 (ru) Способ количественного определения антител к бензо[а]пирену в биологических жидкостях человека
TWI741914B (zh) 檢測心血管疾病的檢驗套組及心血管疾病相關生物標記的濃度檢測方法
TWI741915B (zh) 檢測心血管疾病的檢驗套組及心血管疾病相關生物標記的濃度檢測方法
JP6818348B2 (ja) シスタチンａをマーカーとして用いる癌の検出
CN115704802A (zh) 一种血清蛋白在新型冠状病毒肺炎筛查和诊断中的应用

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
CB03 Change of inventor or designer information
CB03 Change of inventor or designer information

Inventor after: Wang Weiqiang

Inventor before: Shen Dongchang

TA01 Transfer of patent application right
TA01 Transfer of patent application right

Effective date of registration: 20180828

Address after: 301799 room 1201, building B10, North headquarters of Fuyuan Road, Wuqing Development Zone, Tianjin.

Applicant after: Han's joint (Tianjin) Stem Cell Research Institute Co., Ltd.

Address before: 610041 Sichuan University, Sichuan, 17 three South Road, Chengdu.

Applicant before: Shen Dongchang

GR01 Patent grant
GR01 Patent grant